| Species |
Human |
| Protein Construction |
| hFc |
FGL1 (Asp64-Asn305)
Accession # Q08830 |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 90% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Human LAG3, His Tag at 5μg/ml (100μl/Well) on the plate can bind FGL1 hFc Chimera, Human. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
54.8 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 60-66 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in 20mM PB, 250mM NaCl (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Fibrinogen-like protein 1 (FGL-1) is a protein that is structurally related to fibrinogen. In humans, FLG-1 is encoded by the FGL1 gene.Fibrinogen-like protein 1 is a member of the fibrinogen family of proteins, which also includes fibrinogen, fibrinogen-like protein 2, and clotting factors V, VIII, and XIII.Fibrinogen-like Protein 1 is a major immune inhibitory ligand of LAG-3. |
| Synonyms |
FGL1; FGL-1; Hepassocin; HP-041; HFREP-1; LFIRE-1; HFREP1; Lag3 ligand |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
